Machine learning

AI concept
#Artificial intelligence (AI) #Collaboration #Financing #Generative AI #Machine learning

AI-powered drug discovery continues to attract investment

Optimism around the potential role for artificial intelligence (AI) in drug discovery continues, with recent financial deals supporting its use in developing therapeutics for age-related diseases, GPCR-targeting antibodies, DUB-modulating compounds, and novel fusion proteins. AI simulation to advance therapeutics for age-related diseases Biotech Shift Bioscience… Read More

#Business & Investment #News

Future lab, AI and digital data
#Artificial intelligence (AI) #Data #Data automation #Lab of the future #Machine learning #Open Pharma Research #Pistoia Alliance

Lab of the Future survey reveals opinions on the use of AI  

The Pistoia Alliance has released the results of its annual Lab of the Future survey, conducted in partnership with Open Pharma Research. The survey of 200 experts spanning Europe, the Americas and APAC was presented at the Lab of the Future Congress in Amsterdam from 1-2 October 2024.   … Read More

#News

Hopfield and Hinton
#Artificial intelligence (AI) #Machine learning #Nobel Prize #Princeton Neuroscience Institute #University of Toronto

Physics Nobel prize awarded for machine learning inventions

The Princeton Neuroscience Institute’s John Hopfield has been awarded the Nobel Prize in physics for foundational discoveries and inventions that enable machine learning with artificial neural networks. He shares the prize with Geoffrey Hinton of the University of Toronto, who has been referred to as the “Godfather of… Read More

#News

AI roadmap
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Large language model (LLM) #Machine learning

Unlocking AI in drug discovery: A roadmap to scalable solutions

Dr Mutlu Dogruel, Vice President of AI Solutions at Cresset, examines AI’s transformative potential, highlights the current challenges and introduces a series of potential solutions to implement AI in the drug discovery landscape successfully. The use of artificial intelligence (AI) is creating a paradigm shift in… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Machine learning #PhaseV

ML could facilitate increased adoption of adaptive clinical trials

A new machine learning (ML) software platform has been launched to facilitate wider adoption of advanced and adaptive clinical trials. The latest version of AdaptV includes an advanced mode to support more in-depth modifications of relevant algorithmic and statistical parameters that go into trial design, accounting… Read More

#News

Brain Awareness Week
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Clinical trial design #Machine learning

How large language models can elevate clinical research

Deepika Khedekar investigates the use of LLMs in clinical trials and how we can overcome the potential challenges to their wider application. $2.3 billion1 is the estimated cost of bringing a new drug from the drawing board to pharmacy shelves today. Clinical trials make up a… Read More

#Exclusive Content

SLAS Europe 2024
#AI / data analytics / healthtech / informatics #Awards #Drug discovery #Lab automation #Life sciences #Machine learning #SLAS2024

SLAS Europe 2024 in summary  

DDW Multimedia Editor Megan Thomas travelled to SLAS Europe from 27-29 May in Barcelona, Spain. Having attended a range of sessions and spoken to industry attendees and exhibitors, she reflects on the event.   Opening keynote  Professor Luis Serrano presented the opening keynote of the event on engineering… Read More

#Exclusive Content #Trends & Analysis

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Lab automation #Machine learning

Webinar: Using AI, ML and lab automation in drug discovery

In this free webinar, hosted by DDW and sponsored by Benchling, you will learn about technology through the lens of artificial intelligence (AI), machine learning and lab automation. It will take place on 11 June from 3:00 PM – 4:00 PM BST. You will hear from Jonathan… Read More

Webinar date:
Sponsored by Benchling
#News

Robot holds up a pill
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Lab automation #Machine learning

Register for this AI, ML and lab automation webinar now

In this free webinar, hosted by DDW and sponsored by Benchling, you will learn about technology through the lens of artificial intelligence (AI), machine learning and lab automation. It will take place on 11 June from 3:00 PM – 4:00 PM BST. You will hear from Jonathan… Read More

Webinar date:
Sponsored by Benchling
#News

AI and robotics
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Lab automation #Machine learning

How is AI and lab automation impacting drug discovery?

In this free webinar, hosted by DDW and sponsored by Benchling, you will learn about technology through the lens of artificial intelligence (AI), machine learning and lab automation. It will take place on 11 June from 3:00 PM – 4:00 PM BST. You will hear from Jonathan… Read More

Webinar date:
Sponsored by Benchling
#News

#Biomarkers #Machine learning #Phenomix Sciences #Weight loss

Test predicts obesity patients’ response to Ozempic

A new study has demonstrated the clinical utility of a machine-learning gene risk score biomarker to predict patient response to Ozempic (semaglutide) and reduce variability. The study ‘Performance of a Machine-Learning Gene Risk Score Biomarker on Predicting Response to Semaglutide’ was led by the Mayo Clinic… Read More

#News

#AI / data analytics / healthtech / informatics #Antibody-based therapeutics #Artificial intelligence (AI) #Machine learning

Machine learning: Developing next generation antibody therapeutics

Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics. This remarkable progress in antibody modalities for… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Lab automation #Machine learning

Technology: Artificial intelligence, machine learning and lab automation

In this free webinar, hosted by DDW and sponsored by Benchling, you will learn about technology through the lens of artificial intelligence (AI), machine learning and lab automation. You will hear from Jonathan Wingfield, Principal Scientist at AstraZeneca; Abraham Heifets, CEO at Atomwise; Raminderpal Singh, AI Expert at HitchhikersAI; alongside… Read More

Webinar date:
Sponsored by Benchling
#Webinars

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #Machine learning

AI and machine learning: A new era for clinical trials

Fiona Maini, Senior Director Global Compliance & Strategy, at Medidata looks at the rise of artificial intelligence (AI) and machine learning (ML) within life sciences and the applications for the technology in clinical trials. The benefits that AI and machine learning (ML) can bring to society and their potential to… Read More

#Exclusive Content #Trends & Analysis

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Library screening #Machine learning

AI: Advancing drug discovery with ultra-large library processing

Rob Scoffin, CEO, and Matthew Habgood, Principal Computational Chemistry Developer at Cresset, discuss the role of AI/ML in advancing screening methods by utilising virtual screening (VS) approaches to process compound libraries on an ultra-large scale. Drug discovery is a complex process that relies on designing and… Read More

#Exclusive Content

#Artificial intelligence (AI) #Cancer research #Immunotherapy #Machine learning #Oncology #Spatial biology

The biotech improving immunotherapies with AI

DDW Editor Reece Armstrong speaks to Ron Alfa, CEO & Co-founder at NOETIK, about the company’s mission to utilise artificial intelligence (AI) and spatial biology to develop better immunotherapies for cancer patients. Reece A: What are some of the human limitations to current drug discovery research for immunotherapies?… Read More

#Cancer Research #Exclusive Content